On Jan. 11, CMS released a proposed coverage decision that would cover the costs of monoclonal antibody treatments for Alzheimer's Disease patients only if they are enrolled in clinical trials.
On Jan. 6, CMS released a proposed rule that would require pharmacy price concessions be passed to patients at the point-of-sale and reinstate detailed MLR reporting requirements.
On Dec. 28, CMS released a proposed rule that would, in part, propose that adverse tiering is presumptively discriminatory and require that QHP issues offer more standardized plan options.
AMCP has recently published a manuscript in the Journal of Managed Care + Specialty Pharmacy (JMCP) focusing on the significant role that health plans, managed care organizations, prescribers, pharmacists, patients, and others have in decreasing the morbidity and mortality associated with opioid overdose.
As the inaugural Executive Fellow in Health Care Association Leadership, Drake Reiter, PharmD, RPh, recounts his experience working at AMCP. From leading the development of the AMCP Digital Therapeutics Group to participating in board of directors meetings, learn more about his experience.
AMCP responded in a letter to the editor of Health Affairs stressing that managed care tools work to address the misalignment between drug prices and clinical value. In her latest blog post, AMCP CEO Susan Cantrell dives deeper into the reason behind the response and how it supported the need for value-based pricing.